Decitabine

From Wikipedia, the free encyclopedia

You have new messages (last change).

[edit] Dacogen (decitabine)

Indicated for treatment of patients with myelodysplastic syndrome (MDS), including previously treated and untreated, de novo, and secondary MDS of all FAB subtypes and Intermediate-1, Intermediate-2, and High-Risk IPSS groups.[1]

[edit] Basic Information

  • Trade Name: Dacogen
  • Generic Name: decitabine
  • FDA approved: May 2, 2006
  • Chemical Name: 4-amino-1-(2-deoxy-b-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one
  • Classification: antimetabolite
  • Manufacturer: MGI Pharma
Retrieved from "http://en.wikipedia.org../../../d/e/c/Decitabine.html"